Community Research and Development Information Service - CORDIS

  • European Commission
  • CORDIS
  • Projects and Results
  • Periodic Reporting for period 1 - HbMP-700 (The World's First Safe and Efficacious Human Blood Substitute: HbMP-700, a Haemoglobin based oxygen carrier, based on bovine blood.)
H2020

HbMP-700 Report Summary

Project ID: 744585

Periodic Reporting for period 1 - HbMP-700 (The World's First Safe and Efficacious Human Blood Substitute: HbMP-700, a Haemoglobin based oxygen carrier, based on bovine blood.)

Reporting period: 2017-01-01 to 2017-04-30

Summary of the context and overall objectives of the project

About 100 Mio. blood transfusions are performed worldwide p.a. Today, no substitute for human blood as an oxygen carrier exists. CC-Ery develops HbMP-700, the first safe and effective human blood substitute for the use in Red Blood Cell (RBC) concentrates, from an abundant, low cost source: bovine blood.

In Germany alone, every 5 seconds someone needs a RBC transfusion - to compensate for blood loss during surgery, to save lives of accident victims or to treat patients with anaemia. 12.000 lives per day saved in the U.S. by RBC transfusions. Worldwide, global blood supply does not match demand, due to dependency on voluntary donations, short shelf life, difficult storage, risks of disease transmission, and blood type mismatching. This is a recognized problem even in the developed countries:

HbMP-700 can address those problems both in the developed world as well as developing countries. HbMP 700 is the first substitute for human blood as a source for RBC transfusions. Thanks to a sophisticated safety concept aligned with EU guidelines and regulators, no viral agents are transferred to humans3. HbMP- 700 is as effective as human blood, while having superior safety and storage characteristics.

The overall objective is to develop HbMP-700 until market launch to address the above named problems. The objective of the SME I action is to lay the foundation for clinical development, namely a) business case, b) GMP manufacturing concept for the medicinal product to be investigated in clinical trials and c) the synopsis development for the first study in humans (Ph I).

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

The first part of the action – Business Plan – has helped to deepen the understanding of the various indications and target market segments. It is essential in justifying the investment going forward vs. current and future private investors, strategic partners, as well as public funding sources. In addition, it has helped to prioritize possible applications from a market potential perspective, which is an important input for the further clinical development plan.

The second part of the action – detailing of the GMP manufacturing concept – has brought the company a significant step closer to GMP production and such to the start of clinical development with a GMP IMP (Investigational Medicinal Product). The partners for this step have been identified, evaluated and selected, including a back-up option. The concept was validated with regulatory authorities.

The third part of the action – clinical development plan –had as the main output the synopsis for the first clinical study (Ph I) of HbMP-700. It is important for discussions with regulatory authorities (pre-submission meeting), as well as for budgeting and planning of the next private and public funding rounds.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

As a conclusion, the SME I project has brought CC-Ery close to market, reduced the risk of the upcoming development steps, and improved the economic justification of the HbMP-700 project. The manufacturing concept that was developed is unique regarding the performance parameter of HbMP-700 that are achieved. CC-Ery believes it is able to reach clinical stage over the next 12-18 months.

Related information

Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top